Previous research suggests that, while adhesion molecules like ICAM-1 and MAdCAM-1 also contribute to the treatment of inflammatory bowel diseases, selectively blocking VCAM-1 appears to offer higher potential efficacy in managing these conditions. This evidence concerns the gene MADCAM1 and inflammatory bowel disease.